SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-22-148774
Filing Date
2022-05-12
Accepted
2022-05-12 16:49:16
Documents
42
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d347297d10q.htm   iXBRL 10-Q 1345425
2 EX-31.1 d347297dex311.htm EX-31.1 10733
3 EX-31.2 d347297dex312.htm EX-31.2 10317
4 EX-32.1 d347297dex321.htm EX-32.1 5383
  Complete submission text file 0001193125-22-148774.txt   3457750

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA cmpi-20220331.xsd EX-101.SCH 20640
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cmpi-20220331_cal.xml EX-101.CAL 21748
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmpi-20220331_def.xml EX-101.DEF 110626
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpi-20220331_lab.xml EX-101.LAB 177352
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpi-20220331_pre.xml EX-101.PRE 142357
36 EXTRACTED XBRL INSTANCE DOCUMENT d347297d10q_htm.xml XML 314884
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Filer) CIK: 0001651431 (see all company filings)

IRS No.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39425 | Film No.: 22918632
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences